Ofatumumab is a cancer medication that’s awaiting approval by the U.S. Food and Drug Administration and the European Medicines Agency to treat MS patients. It’s delivered by injection once a month and aims to reduce MS inflammation by targeting a certain type of B-cell. If approved, it would be the first B-cell therapy that can be self-injected at home.
Aubagio (teriflunomide) is a once-a-day pill that targets B-cells and T-cells. It’s been in use for several years, and I was treated with it at one time. Would I have switched to a “superior” ofatumumab if it had been available? Probably not, even if it proved to be more effective. One of the reasons I was using Aubagio was to get away from giving myself an injection.
Novartis‘ ofatumumab outperformed Aubagio (teriflunomide) at lowering the frequency of relapses and preventing disability progression among people with relapsing forms of multiple sclerosis (MS), a study based on clinical trial data reports.
The study, “Ofatumumab versus Teriflunomide in Multiple Sclerosis,” was published in The New England Journal Of Medicine.
Click here to read the full story.
Here’s another study involving Aubagio. I’m glad that it’s been shown to be safe and effective over a period of four to six years. I might still be using it were it not for my facing a steep co-pay when I changed from my employer’s insurance to Medicaid several years ago.
Aubagio (teriflunomide), taken as a 14 mg tablet once a day, shows long-term safety and efficacy in patients with relapsing forms of multiple sclerosis (MS), according to results of the Phase 3 TOWER extension study.
Treatment was generally well tolerated by the 751 patients using Aubagio for a median of 4.2 years, and up to 6.3 years, in this extension trial, with side effects remaining consistent with those reported in earlier studies, and long-term disease stabilization evident, its researchers reported.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?